Mental Health Clinics in Marion, MT Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Change Academy At Lake Of The Ozarks Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 9705 Lost Prairie Rd, Marion, MT 59925 Phone: 480-550-9281 |
Anne E Murphy, Llc Clinic - Adult Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1570 Bitterroot Lane, Telehealth Provider, Marion, MT 59925 Phone: 406-261-5869 |
News Archive
FDA grants Fast Track designation to Corthera's relaxin for treating acute heart failure
Corthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to relaxin, the company's investigational drug for the treatment of acute heart failure (AHF). The Fast Track program facilitates the development and expedites the review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis
Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis as physician researchers.
Researchers enhance capabilities of solid-state nanopores
The latest advance in solid-state nanopore sensors - devices that are made with standard tools of the semiconductor industry yet can offer single-molecule sensitivity for label-free protein screening - expands their bag of tricks through bionanotechnology.
HSS summit: Current classification system for osteoarthritis is inadequate
A recent summit that brought together international multidisciplinary experts has provided a foundation for addressing what is the leading cause of disability in the United States: osteoarthritis.
Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
› Verified 3 days ago